This preprint is under consideration at BMC Pharmacology and Toxicology. Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.
Learn more about In Review
Research article
Dramatic neurological and biological effects by Botulinum Neurotoxin Type A on SH-SY5Y neuroblastoma cells, beyond the blockade of neurotransmitter release
Bal R. Singh
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9069-1487
License:
This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Background Gene expression profile analysis on mammalian cell lines and animal models after exposure to botulinum neurotoxin (BoNT) have been investigated in several studies in recent years. This provides a powerful tool to identify critical signaling pathways involved in the biological and inflammatory responses to BoNT and helps to determine the mechanism of the function of botulinum toxins.
One of the key clinical characteristics of BoNT is its prolonged on-site effects. The role of BoNT on the blockage of neurotransmitter acetylcholine release in the neuromuscular junction has been well established. However, the effects of the treatment time of BoNT on the human cellular model and its potential mechanism remain to be defined. This study is aimed to use the gene microarray technology to compare the two physiological critical time points of BoNT type A (BoNT/A) treatment of human neuroblastoma cells and to advance our understanding of the profound biological influences that toxin molecules play in the neuronal cellular system.
Results SH-SY5Y cells were treated with BoNT/A for 4 and 48 hours which represent the time needed for the entrance of toxin into the cells and the time necessary for the initial appearance of the on-site effects after BoNT application. A comparison of the two time points identified 122 functional groups that are significantly changed. The top five groups are the alternative splicing, phosphoprotein, nucleus, cytoplasm, and acetylation. Furthermore, after 48 hours there were 744 genes significantly up-regulated and 624 genes significantly down-regulated (p‹ 0.01). These genes fell into the following neurological and biological annotation groups: Nervous system development, proteinaceous extracellular matrix, signaling pathways regulating pluripotency of stem cells, cellular function and signal transduction, and apoptosis.
We have also noticed that the up-regulated groups contained neuronal cell development, nervous system development, and metabolic processes while the down-regulated groups contained many chromosomes and cell cycle categories.
Conclusions The effects of BoNT/A on neuronal cells extend beyond blocking the neurotransmitter release, and that BoNT/A is a multifunctional molecule that can evoke profound cellular responses which warrant a more in-depth understanding of the mechanism of the toxin’s effects after administration.
Keywords
Gene expression profile, Clostridium botulinum, Botulinum neurotoxin type A, host response, microarray analysis, Neuroblastoma SH-SY5Y cells, zinc, neurological signaling pathways, biological signaling
Figure 1
Figure 2
Figure 3
Besides being known as the most potent poison known to humankind which causes botulism, Botulinum neurotoxin (BoNT) is also a multifunctional molecule which can be used to treat medical conditions such as muscle hyperactivity (Brisinda, Civello, Albanese, & Maria, 2003), neuromuscular disorders (Coffield, 2003), various types of pain (Ruscheweyh et al., 2018), and treatment of wrinkles(Jacob, 2003). New applications of BoNT have been continuously discovered in the past decade (Ghanem, Raheem, AbdelRahman, Johnson, & Abdel-Raheem, 2018; Sandrini, De Icco, Tassorelli, Smania, & Tamburin, 2017; Wissel, 2018). The mechanisms for BoNT to cause botulism have been well established. BoNT acts preferentially on peripheral cholinergic nerve terminals to inhibit acetylcholine release resulting in flaccid muscle paralysis (Schiavo, Matteoli, & Montecucco, 2000). However, the mechanisms of BoNT as an effective treatment for multiple medical conditions are currently unclear.
Among all the seven toxin serotypes produced by C. botulinum, both BoNT type A (BoNT/A) and type B (BoNT/B) are used in treating medical conditions, and the duration of BoNT/A has the most sustained action in both laboratory animals and human beings. In an effort to investigate the mechanisms of BoNT as an effective neuromedicine, more and more studies indicate that BoNT is not only a toxin but also a multifunctional molecule that participates in the regulation of gene expressions and metabolic pathways (Y. J. Kim et al., 2015; Mukund, Ward, Lieber, & Subramaniam, 2018; T. H. Park, Park, Chang, & Rah, 2016). BoNT/A has been shown to influence cellular dynamics via the modification of cellular apoptosis and cellular proliferation, which can play a role in the expression of genes relevant to abnormal fibroblast proliferation (Xiaoxue, Xi, & Zhibo, 2014). In the murine alveolar macrophage RAW264.7 cell line, microarray analysis reveals that BoNT/A induces host immune cell response through a TLR2-dependent manner (Y. J. Kim et al., 2015), and in another study, BoNT/B has been shown to induce the expression of multiple proinflammatory cytokine genes in a murine dry eye model (C. Y. Park et al., 2007). A previous microarray study in SH-SY5Y cells from our group has found that there were significant changes of genes that involved in neuroinflammatory, ubiquitin-proteasome degradation, and calcium signaling after BoNT/A treatment compared to the untreated control culture (Thirunavukkarasusx et al., 2011). However, most of the current cellular gene expression studies were conducted at one fixed time point; the genomic responses to BoNTs across different time periods have not been fully clarified.
A transcriptomic profiling study that examined the effects of BoNT/A on rat tibialis anterior muscles over one year identified dramatic transcriptional adaptation effects to BoNT/A (Mukund et al., 2014). Another microarray analysis study has investigated the muscle recovery from paresis and atrophy after intramuscular injection of BoNT/A in Juvenile rats. The microarray transcriptional profiling and real-time-PCR analysis identified a sequence of cellular events that leads to the neuromuscular junction regeneration and skeletal muscle functional recovery, and the insulin-like growth factor-1 (IGF-1) signaling pathway is proven to play a central role in the process (Shen et al., 2006). None of the studies, however, have examined the progression of the BoNT effect on gene expression with time. Microarray analysis that focuses on the cellular response over a period of time will provide new insight into the critical signaling pathways involved in the biological and inflammatory responses to BoNT.
In vitro models for the entry of BoNT into neurons have shown that at least 4-hours is needed for BoNT to enter the neuron cells (Dong et al., 2008). Our group has also observed the binding and co-localization of BoNT/A with intracellular structures in SH-SY5Y cells after 4-hours of treatment (Wang, Sun, Yang, Lindo, & Singh, 2014). In both the clinical administrations of BoNT and the in vivo or in vitro BoNT treatment systems, the on-site effect usually takes about 24 to 72 hours (Nigam & Nigam, 2010). In addition, a previous study from our group has observed a significant increase of proinflammatory cytokines release from the SH-SY5Y cells after 48-hours of BoNT/A treatment (Wang et al., 2014) indicating the effectiveness of the duration on evoking the cellular response.
Our current study aims to explore the differences of gene expression profiles in human neuroblastoma SH-SY5Y cells after exposure to BoNT/A at two physiological critical time points: at 4-hours when BoNT/A has made its entry into the cells and at the time of the observation of evoked host responses by BoNT/A which is usually 48-hours. Comparative analysis of gene expression at the two time points identified 122 functional groups that are significantly changed in the neuronal cells. The top five groups are alternative splicing, phosphoprotein, nucleus, cytoplasm, and acetylation. Furthermore, 744 genes were significantly up-regulated after 48 hours, and 624 genes were significantly down-regulated (p‹ 0.01). These genes generally belonged to nervous system development, proteinaceous extracellular matrix, signaling pathways regulating pluripotency of stem cells, cellular function and signal transduction, and apoptosis, suggesting a substantial biological and neurological impact of BoNT treatment.
2.1 Materials
The 150 kDa BoNT/A holotoxin was purchased from Metabiologics Inc. (Madison, WI). The toxin was produced by a Hall A strain of Clostridium botulinum. Toxin activity for the holotoxin was 2.1x107 MLD50/mg according to the manufacturer. The human neuroblastoma cell line SH-SY5Y was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Tissue culture media were ATCC-formulated Eagle’s Minimum Essential Medium (ATCC) with 10% fetal bovine serum (ATCC). Other materials and reagents include Ethanol (70% and 96-100%), Sterile, RNase-free pipet tips, 1.5 ml or 2 ml microcentrifuge tubes, Microcentrifuge for centrifugation at 4 ⁰C and at room temperature. 60 mm treated petri dishes (Lab-Tek II, Nalge Nunc International, Naperville, IL). 4% Paraformaldehyde (Sigma-Aldrich, St. Louis, MO). miRNeasy Mini Kit (Qiagen).
2.2 Cell culture and treatments
The SH-SY5Y cell line, derived from human brain neuroblastoma (Ross, Spengler, & Biedler, 1983), grown and maintained as recommended by ATCC, was maintained with 10% FBS in 5% CO2/humidified air at 37⁰C. SH-SY5Y cells grew as a mixture of floating and adherent cells. The base growth medium was 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium and F12 Medium. To complete the growth medium, fetal bovine serum was added to a final concentration of 10%. The SH-SY5Y cells were seeded at a density of 2×105 cells/well in 60 mm treated petri dishes and grew for 2 days when reaching the 80% confluence before treatment with serum-free media containing 5 nM of BoNT/A for 4 and 48-hours in duplicates.
2.3 RNA extraction
The following protocol was developed from manufacturer Qiagen’s manuals with modifications. At the end of treatment, QIAzol Lysis Reagent was used to added to disrupt and homogenize the SH-SY5Y cells. The upper aqueous phase was collected and treated with 100% ethanol and transferred into the RNeasy Mini column in 2 ml collection tube. After centrifugations, discarded the flow-through. RNeasy Mini columns were transferred to a new 1.5 ml collection tube. Pipetted 30 ml RNase-free water directly onto the RNeasy Mini column membrane. Closed lid, centrifuged for 1 min at 8000 Xg to elute. The concentration of RNA was determined by measuring the absorbance at 260 nm in a spectrophotometer.
2.4 Microarray analysis
Genome analysis was carried out using Affymetrix U133 Plus 2 arrays. After preprocessing and normalization of the data, differentially expressed genes were identified by performing an analysis of variance using Partek Genomics Suite software (Partek Inc., St. Louis, MO). A gene list was created by filtering for p-value <0.01. This subset of 1368 genes was further analyzed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 to identify biologically enriched groups (Huang da, Sherman, & Lempicki, 2009a, 2009b).
The current study identified 1,368 differentially expressed genes between the two time points. As presented in the heat map in Figure 1, 744 genes were up-regulated, and 624 genes were down-regulated, indicating that there are significant differences between the gene expression profile for 48 and 4-hour treatment of the SH-SY5Y cells.
Among the 1,368 differentially expressed genes of the 48-hour to 4-hour treatment, we conducted DAVID analysis and identified 122 functional groups that have been significantly changed in the SH-SY5Y cells. Figure 2 shows the functional annotation chart of the top 20 functional groups according to the number of genes involved.
We took a closer look into the five groups which have involved the most numbers of genes out of the 20 top functional groups and included the results in Table 1. The results table include the numbers of involved genes, p-value, the numbers of up- or down-regulated genes (probe), and the fold change range for up- and down-regulation. These five groups are alternative splicing, phosphoprotein, nucleus, cytoplasm, and acetylation. These results indicate that following the entrance of BoNT/A into the SH-SY5Y cells after 4-hour treatment, when the BoNT/A incubation reaches the 48-hours, different cellular transcription, modification, and signaling transduction pathways ensue with profound cellular responses resulting from dramatic gene fold changes.
We have further investigated the major annotation groups that are involved in neuronal and biological functions. The complete gene list with more than 2-fold change are shown in the following supplement tables: neurological function (Supplement Table 1), neurological cellular response (Supplement Table 2), cell structure related function (Supplement Table 3), and the cell fate determination (Supplement Table 4). In each of these groups, genes were listed according to their DAVID annotation group with the fold change of up- or down-regulation.
Based on the results in Supplement Table 1 through 4, we generated Table 2 below that provides a highlight of the genes with more than 8-fold change after 48-hour treatment. The genes are listed according to their annotation groups.
Dramatic up-regulation of genes involved in acetylcholine receptor and other extracellular components
In the nervous system development annotation group, compared to the 4-hour treatment, three genes have been significantly up-regulated after 48-hour treatment: CHRM3, SPOCK1, and NELL1.
The cholinergic receptor muscarinic 3 (CHRM3) that encodes the CHRM3 receptor has a 32.28-fold increase (p<0.002). The muscarinic receptors (MRs) are G protein-coupled receptors that mediate cholinergic neurotransmission (Eglen, 2006; Pedersen, Bergqvist, & Larhammar, 2018). The CHRM3 receptor responds to the transmitter acetylcholine (Pedersen et al., 2018). The role of muscarinic receptors in the contraction of smooth muscle, particularly of airway, ileum, iris, and bladder, is considered a classical muscarinic response mediated primarily by M3-muscarinic receptors expressed on the smooth muscle cells (Caulfield, 1993). Five MR are identified (designated M1R–M5R, encoded by CHRM1-5). Post-MR signaling involves activation of phospholipase C with subsequent changes in cellular levels of inositol phosphate, cAMP, and calcium (McLean et al., 2016).
The sparc/osteonectin cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1) gene that encodes the protein Testican has a 17.07-fold increase (p<0.002). Testican is a human testicular proteoglycan which contains the extracellular calcium-binding module (Alliel, Perin, Jolles, & Bonnet, 1993). Immunostaining in the adult normal mouse muscle has shown the co-localization of SPOCK and acetylcholine receptor (AChR) clusters (Cifuentes-Diaz et al., 2000).
The NELL1 gene, which is a secretory osteogenic protein and functions as an extracellular matrix component (Li et al., 2018) has a 16.95 fold increase (p<0.002). The dramatic expression increase of this group of genes after 48-hour treatment indicates that after the acetylcholine release being blocked by BoNT/A, the genes involved in the expression of the acetylcholine responsive receptor, the extracellular components in the SH-SY5Y cells are dramatically up-regulated, highly possible to compensate the transmitter loss.
Another significantly up-regulated gene is Rho GTPase activating protein 36 (ARHGAP36) whose expression increased 11.66-fold (p<0.003). Rho, a Ras homologue of small GTPase, is present from yeast to mammals. It shuttles between the active GTP-bound form and the inactive GDP-bound form and works as a switch in stimulus-evoked cell adhesion and motility, enhancement of contractile responses, and cytokinesis (Narumiya, 1996). In these actions, Rho directs the reorganization of the actin cytoskeleton at a specific time and a particular site in the cell (Hall, 1992). ARHGAP36 is expressed in neuroblastoma cells and promotes aberrant activation of the Hedgehog pathway and inhibits Protein kinase A (PKA) signaling (Eccles et al., 2016). PKA is a key mediator of cAMP signaling downstream of G-protein-coupled receptors, a signaling pathway conserved in all eukaryotes. The up-regulation of ARHGAP36, in turn, dampens the sensitivity of cells to cAMP (Eccles et al., 2016).
Significant downregulation of genes for collagen deposition and cellular differentiation and apoptotic factors
Collagen type I makes up 90% of the collagen in the human body, and its function is to give the tissue resistance to force. Collagen type I is also one of the main components of the human skin dermis. The gene COL1A1 and COL1A2 encode the pro-alpha 1 and pro-alpha 2 chains of type I collagen, respectively (Olsen, Peltonen, Jaakkola, Chu, & Uitto, 1989). Compared to 4-hour treatment, we observed an 11.99-fold decrease (p<0.009) of COL1A2 gene expression after 48 hours. However, the Collagen-degrading matrix metalloproteinases (MMPs) gene expression did not show a significant difference between our 48 and 4-hour treatment. This finding indicates that although BoNT/A has down-regulation effects on the collagen extracellular matrix formation genes, the collagen degradation genes are not influenced by the 48 vs. 4-hour treatment.
We have also identified the downregulation of several genes that are involved in cell differentiation and survival. There are four known inhibitors of DNA binding (ID) proteins (ID1, ID2, ID3, andID4) which share a homologous HLH domain, but lack the basic DNA binding region. The basic helix-loop-helix (bHLH) family of transcription factors are critical cell type determinants that play essential roles in cellular differentiation (Massari & Murre, 2000). We observed an 8.13 (p<0.006) and 31.23 (p<0.001)-fold down-regulation of ID3 and ID2, respectively. ID3 also regulates cytokines, including chemokine (C–X–C motif) ligand 1 previously known as GRO1, interleukin-6 (IL-6) and IL-8 (Jin et al., 2011). We have observed a 13.26 fold decrease (p<0.005) in the insulin-like growth factor binding protein 3 (IGFBP3). IGFBP regulates the bioavailability and bioactivity of insulin-like growth factor (IGF). The major IGFBP in serum is IGFBP-3. IGFBP-3 regulates IGF bioactivity and also independently modulates cell growth and survival (Dake, Boes, Bach, & Bar, 2004). There is also a 26.63-fold decrease (p<0.007) of serum- and glucocorticoid-inducible kinase 1 (SGK1) genes that belong to the AGC family of kinases and have been shown to have various cellular functions, including the promotion of cell survival.
BoNT/A evokes profound up and down-regulation of genes to impact physiological processes in SH-SY5Y cells
Besides looking into individual genes, to generate a thorough understanding of the effects of BoNT/A on the neurological and biological annotation groups, we ran a further analysis of the genes and determined whether the 48-hour treatment evokes the up- or down-regulation of different annotation groupsas shown in Figure 3. Interestingly, there were no overlaps in the functional groups between the two up- and down-regulation group sets.We have also noticed that the up-regulated groups contained neuronal cell development, nervous system development, and metabolic processes; the down-regulated groups contained many chromosomes and cell cycle categories. These data indicate that BoNT/A treatment has profound effects on the neuronal and non-neuronal functions of SH-SY5Y cells. Moreover, the up and down-regulation of genes is coordinated to impact physiological processes.
Nerve terminal intoxication and the medical application of BoNT/A are fully reversible and are not reported to lead to any neurodegeneration. After the synaptic blockade of cholinergic nerve terminals, new synapses are formed by the neuron (sprouting) to replace its original ones (de Paiva, Meunier, Molgo, Aoki, & Dolly, 1999). In the cellular model of cerebellar granule cells, BoNT/A did not trigger neurite degeneration or apoptosis up to 72-hour treatment (Berliocchi et al., 2005). In this study, we have demonstrated that BoNT/A significantly modified genes involved in the annotation group of nervous system development and the proteinaceous extracellular matrix. The three genes CHRM3, SPOCK1, and NELL1 have been increased 32.28, 17.07, and 16.95 fold, respectively (Table 2). A study in the human induced pluripotent stem cell (hiPSC)-derived neurons also found that BoNT/A induced the upregulation of CHRM3 by 9 fold compared to the non-treated control which promotes the neurite outgrowth (Huh et al., 2009; Scherf et al., 2014). The SPOCK1 gene encoded the protein testican whose functions are to regulate cell shape and gene expression, cell adhesion processes, and neurogenesis (Lane & Sage, 1994). This protein has also been shown to contribute to neuron-neuron synapse development and is involved in neuron-muscle synapse development (Kohfeldt, Maurer, Vannahme, & Timpl, 1997; Meier & Wallace, 1998). In a mature mouse model, the co-localization of SPOCK protein and acetylcholine receptor (AChR) clusters has been observed (Cifuentes-Diaz et al., 2000). But botulinum toxins have been shown to induce a remodeling of AChR clusters (Koltgen, Ceballos-Baumann, & Franke, 1994), and AChR clusters devoid of SPOCK were observed after BoNT/A injection in an extensor digitorum longus muscle model (Cifuentes-Diaz et al., 2000). In our study, this effect may also interact with the up-regulation of CHRM3, which activates the phospholipase C and, in turn, modifies the cellular level of cAMP. The evoking of a series of signal transduction effort in the cell after BoNT/A 48-hour treatment demonstrates that the modification of cellular function and signal transduction are part of the on-site effects of BoNT/A. These data indicate that although we observed the significant up-regulation of CHRM3 and SPOCK1 genes which may, in turn, promote the increase of the expression of the receptors in the cells, this doesn’t gurantee the rise in the co-localization of the clusters of the related receptors. This finding calls attention to the further investigation of these receptors and their downstream signaling after BoNT/A treatment.
In addition to the genetic mechanism involved in the intoxication recovery, we have also identified the effects of BoNT/A in other biological functions as a neuromedicine. BoNT has been shown to inhibit hypertrophic scar formation (Xiao & Qu, 2012) and modulate the release of various neurotransmitters, such as glutamate and substance P, which will help reduce scar hypertrophy (Al-Qattan, Al-Shanawani, & Alshomer, 2013). We have identified the expression of different genes involved in collagen deposition in hypertrophic scars, and neurotransmitters that are involved in scar formation (Table 2 and Supplement Table 2). We observe an 11.99 fold decrease of the COL1A2 gene expression after 48-hour treatment compared to 4-hour. The gene COL1A1 and COL1A2 encode the pro-alpha 1 and pro-alpha 2 chains of type I collagen, respectively. Collagen type I makes up 90% of the collagen in the human body, and its function is to give the tissue resistance to force. Collagen type I is also one of the main components of the human skin dermis (Olsen et al., 1989). In our study, the Collagen-degrading matrix metalloproteinases (MMPs) gene expression did not show a significant difference between our 48 and 4-hour treatment groups. BoNT/A has been shown to block the syntheses of collagen types 1 and 3 in human fibroblasts upon the stimulation with TGF (S. Kim et al., 2016). In another study on the human dermal fibroblasts, type III collagen mRNA expression has been significantly decreased when BoNT/A was administrated on KFs regardless of the presence or absence of TGF-ß (Oh et al., 2012).
It has been reported that BoNT/A inhibits the release of various neurotransmitters (e.g., glutamate and substance P), which inhibits the release of inflammatory mediators such as bradykinin, prostaglandins, and serotonin.6 (Al-Qattan et al., 2013). A previous microarray study in SH-SY5Y cells from our group has found that there were significant changes of genes that involved in neuroinflammatory, ubiquitin-proteasome degradation, and calcium signaling after BoNT/A treatment compared to the untreated control culture (Thirunavukkarasusx et al., 2011). Our data (Supplement Table 3) shows the profound effects of BoNT/A in the cytoskeleton involved genes after 48-hour treatment. In addition, as shown in Table 2, the signaling pathways regulating the pluripotency of stem cells, cell division, and apoptosis functions have also been significantly modified by the 48-hour treatment. These included key regulators that signal cytoskeletal remodeling steps in pathways related to vesicle trafficking, axonal growth, and cell migration. These proteins included the Rho GTPase, Ras-GAP SH3 binding protein, Rho GTPase activating protein, actin-related protein, and actin, which affect the phosphorylation of proteins involved in cytoskeletal remodeling pathways (Lee, Ahn, Park, & Park, 2016). We have also observed a 26.6-fold decrease of SGK1 genes. Several observations point to a physiological role of SGK1 in cell cycle progression (Buse et al., 1999) and cell survival pathways. The upregulation of SGK1 strongly correlates with the occurrence of cell death (Schoenebeck et al., 2005). Our data indicate that BoNT/A has a strong inhibition effect on SGK1 expression, which may prevent the apoptosis of the SH-SY5Y cells.
No currently available publication has explored the effects of BoNT/A on the inhibition of DNA binding 2 or 3 (ID2 or ID3) expression. We have observed an 8.13 and 31.23 fold down-regulation of ID3 and ID2. In a study using human glioma cell line Hs683, candoxin which is a three-finger neurotoxin purified from the venom of the Malayan krait (Bungarus candidus) snake has been shown to downregulate ID3 which inhibits glioma cell proliferation (Jiang, Ma, & Cheng, 2012). The cytokines that regulated by ID3 genes, including chemokine (C–X–C motif) ligand one previously known as GRO1, interleukin-6 (IL-6), and IL-8 (Jin et al., 2011). Our data indicate that BoNT/A has the capability of modifying DNA binding factors, which may link to the longevity of BoNT/A treatment since the BoNT/A effect is extended into the transcriptional regulation and is not solely determined by the toxin protein half-life in the application sites. This observation sheds light on another mechanism to explain why the on-site effects of the BoNT/A treatment can last up to 16 weeks.
One of the advantages of BoNT/A medicinal application is the local effect at the neuromuscular junction (NMJ), resulting in flaccid paralysis. It has been believed that BoNT inhibits synaptic transmission only near the site of injection (Wheeler & Smith, 2013). However, there has been evidence questioning this idea after physicians utilized this agent in human patients. For example, after peripheral injection of BoNT/A, reciprocal inhibition between agonist and antagonist muscles has been reported, raising the possibility that BoNT/A moves within networks of neurons to affect circuit function (Aymard, Giboin, Lackmy-Vallee, & Marchand-Pauvert, 2013; Marchand-Pauvert et al., 2013). Alternatively, the observed effects might be due to the compensatory reorganization and remodeling of neuronal networks upstream of the injection site, as a result of purely local effects on the initial uptake neurons (Abbruzzese & Berardelli, 2006; Boroojerdi, Cohen, & Hallett, 2003; Curra, Trompetto, Abbruzzese, & Berardelli, 2004). In a study conducted in the compartmentalized microfluidic devices, BoNT/A and D have undergone interneuronal transfer to affect networks of neurons (Bomba-Warczak et al., 2016). These findings suggest a possible mechanism for the potential side effects after the BoNT application.
The primary conclusion of the current study is that botulinum neurotoxin type A can cause dramatic neurological and biological effects on SH-SY5Y neuroblastoma cells. From the time BoNT/A enters the SH-SY5Y cells at 4-hours to the evoking of on-site effects of BoNT/A after 48-hours, the toxin has profound influences on gene expression profiles of SH-SY5Y cells. We identified significant expression changes of genes in the functional groups of nervous system development, proteinaceous extracellular matrix, signaling pathways regulating pluripotency of stem cells, cellular function and signal transduction, and apoptosis. Up-regulated groups contained neuronal cell development, nervous system development, and metabolic processes; while the down-regulated groups contained many chromosomes and cell cycle categories. Collectively, this experimental evidence strongly supports the overall conclusion that BoNT/A has profound neurological and biological effects on human neuroblastoma SH-SY5Y cells, which extend beyond the neurotransmitter release blockage. Our research warrants a more in-depth understanding of the mechanism of the toxin’s effects after the administration, which will help to understand the development of botulism disease and its longevity and explain the effectiveness of BoNT-related biomedicineIn future studies we plan to include treatment times longer than 48 hours which will provide more comprehensive data for the understanding of the mechanism of the toxin’s effects after administration. Our data and the clinical evidence demonstrate that BoNT interacts with host systems in a more sophisticated manner than was initially envisioned, prompting the need for further investigations of the neurons and non-neuronal biology after the BoNT application.
BoNT, botulinum neurotoxin; BoNT/A, botulinum neurotoxin type A; HC, heavy chain; LC, light chain; IGF-1, insulin-like growth factor-1; IL-6, interleukin-6
Ethics approval and consent to participate
Not applicable
Consent to publish
Not applicable
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.
Competing interests
The authors declare that they have no competing interests
Funding
This work was supported by Merz Pharmaceuticals, Frankfurt, Germany, and Maryada Foundation.
Authors' Contributions
LW, data curation, investigation, writing – original draft preparation
CSR, formal analysis, writing – review, and editing
BRS: supervision, writing- review, and editing, corresponding author.
All authors read and approved the final manuscript
Acknowledgments
Data analysis for this project was carried out at Dartmouth Medical School in the Genomics Shared Resource with the assistance from Dr. Fred Kolling IV.
Abbruzzese, G., & Berardelli, A. (2006). Neurophysiological effects of botulinum toxin type A. Neurotox Res, 9(2-3), 109-114.
Al-Qattan, M. M., Al-Shanawani, B. N., & Alshomer, F. (2013). Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. Ann Saudi Med, 33(5), 482-488. doi:10.5144/0256-4947.2013.482
Alliel, P. M., Perin, J. P., Jolles, P., & Bonnet, F. J. (1993). Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur J Biochem, 214(1), 347-350.
Aymard, C., Giboin, L. S., Lackmy-Vallee, A., & Marchand-Pauvert, V. (2013). Spinal plasticity in stroke patients after botulinum neurotoxin A injection in ankle plantar flexors. Physiol Rep, 1(6), e00173. doi:10.1002/phy2.173
Berliocchi, L., Fava, E., Leist, M., Horvat, V., Dinsdale, D., Read, D., & Nicotera, P. (2005). Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis. J Cell Biol, 168(4), 607-618. doi:10.1083/jcb.200406126
Bomba-Warczak, E., Vevea, J. D., Brittain, J. M., Figueroa-Bernier, A., Tepp, W. H., Johnson, E. A., . . . Chapman, E. R. (2016). Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons. Cell reports, 16(7), 1974-1987. doi:10.1016/j.celrep.2016.06.104
Boroojerdi, B., Cohen, L. G., & Hallett, M. (2003). Effects of botulinum toxin on motor system excitability in patients with writer's cramp. Neurology, 61(11), 1546-1550. doi:10.1212/01.wnl.0000095965.36574.0f
Brisinda, G., Civello, I. M., Albanese, A., & Maria, G. (2003). Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. Curr Med Chem, 10(7), 603-623.
Caulfield, M. P. (1993). Muscarinic receptors--characterization, coupling and function. Pharmacol Ther, 58(3), 319-379. doi:10.1016/0163-7258(93)90027-b
Cifuentes-Diaz, C., Alliel, P. M., Charbonnier, F., de la Porte, S., Molgo, J., Goudou, D., . . . Perin, J. P. (2000). Regulated expression of the proteoglycan SPOCK in the neuromuscular system. Mech Dev, 94(1-2), 277-282.
Coffield, J. A. (2003). Botulinum neurotoxin: the neuromuscular junction revisited. Crit Rev Neurobiol, 15(3-4), 175-196.
Curra, A., Trompetto, C., Abbruzzese, G., & Berardelli, A. (2004). Central effects of botulinum toxin type A: evidence and supposition. Mov Disord, 19 Suppl 8, S60-64. doi:10.1002/mds.20011
de Paiva, A., Meunier, F. A., Molgo, J., Aoki, K. R., & Dolly, J. O. (1999). Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A, 96(6), 3200-3205.
Dong, M., Liu, H., Tepp, W. H., Johnson, E. A., Janz, R., & Chapman, E. R. (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Molecular biology of the cell, 19(12), 5226-5237. doi:10.1091/mbc.E08-07-0765
Eccles, R. L., Czajkowski, M. T., Barth, C., Müller, P. M., McShane, E., Grunwald, S., . . . Rocks, O. (2016). Bimodal antagonism of PKA signalling by ARHGAP36. Nat Commun, 7, 12963. doi:10.1038/ncomms12963
Eglen, R. M. (2006). Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol, 26(3), 219-233. doi:10.1111/j.1474-8673.2006.00368.x
Ghanem, H., Raheem, A. A., AbdelRahman, I. F. S., Johnson, M., & Abdel-Raheem, T. (2018). Botulinum Neurotoxin and Its Potential Role in the Treatment of Erectile Dysfunction. Sex Med Rev, 6(1), 135-142. doi:10.1016/j.sxmr.2017.07.008
Hall, A. (1992). Ras-related GTPases and the cytoskeleton. Mol Biol Cell, 3(5), 475-479. doi:10.1091/mbc.3.5.475
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009a). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 37(1), 1-13. doi:10.1093/nar/gkn923
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009b). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4(1), 44-57. doi:10.1038/nprot.2008.211
Huh, J. W., Kim, Y. H., Lee, S. R., Kim, H., Kim, D. S., Kim, H. S., . . . Chang, K. T. (2009). Gain of new exons and promoters by lineage-specific transposable elements-integration and conservation event on CHRM3 gene. Mol Cells, 28(2), 111-117. doi:10.1007/s10059-009-0106-z
Jacob, C. I. (2003). Botulinum neurotoxin type B--a rapid wrinkle reducer. Semin Cutan Med Surg, 22(2), 131-135. doi:10.1053/sder.2003.50009
Jiang, Y. X., Ma, Y., & Cheng, Y. (2012). Transcriptome and coexpression network analysis of the human glioma cell line Hs683 exposed to candoxin. J Int Med Res, 40(3), 887-898. doi:10.1177/147323001204000307
Jin, X., Yin, J., Kim, S. H., Sohn, Y. W., Beck, S., Lim, Y. C., . . . Kim, H. (2011). EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res, 71(22), 7125-7134. doi:10.1158/0008-5472.CAN-11-1330
Kim, S., Ahn, M., Piao, Y., Ha, Y., Choi, D. K., Yi, M. H., . . . Oh, S. H. (2016). Effect of Botulinum Toxin Type A on TGF-beta/Smad Pathway Signaling: Implications for Silicone-Induced Capsule Formation. Plast Reconstr Surg, 138(5), 821e-829e. doi:10.1097/prs.0000000000002625
Kim, Y. J., Kim, J. H., Lee, K. J., Choi, M. M., Kim, Y. H., Rhie, G. E., . . . Shin, N. R. (2015). Botulinum neurotoxin type A induces TLR2-mediated inflammatory responses in macrophages. PLoS One, 10(4), e0120840. doi:10.1371/journal.pone.0120840
Kohfeldt, E., Maurer, P., Vannahme, C., & Timpl, R. (1997). Properties of the extracellular calcium binding module of the proteoglycan testican. FEBS Lett, 414(3), 557-561.
Koltgen, D., Ceballos-Baumann, A. O., & Franke, C. (1994). Botulinum toxin converts muscle acetylcholine receptors from adult to embryonic type. Muscle Nerve, 17(7), 779-784. doi:10.1002/mus.880170713
Lane, T. F., & Sage, E. H. (1994). The biology of SPARC, a protein that modulates cell-matrix interactions. Faseb j, 8(2), 163-173.
Lee, J., Ahn, E., Park, W. K., & Park, S. (2016). Phosphoproteome Profiling of SH-SY5y Neuroblastoma Cells Treated with Anesthetics: Sevoflurane and Isoflurane Affect the Phosphorylation of Proteins Involved in Cytoskeletal Regulation. PLoS One, 11(9), e0162214. doi:10.1371/journal.pone.0162214
Li, C., Zheng, Z., Jiang, J., Jiang, W., Lee, K., Berthiaume, E. A., . . . Soo, C. (2018). Neural EGFL-Like 1 Regulates Cartilage Maturation through Runt-Related Transcription Factor 3-Mediated Indian Hedgehog Signaling. Am J Pathol, 188(2), 392-403. doi:10.1016/j.ajpath.2017.09.020
Marchand-Pauvert, V., Aymard, C., Giboin, L. S., Dominici, F., Rossi, A., & Mazzocchio, R. (2013). Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol, 591(4), 1017-1029. doi:10.1113/jphysiol.2012.239178
Massari, M. E., & Murre, C. (2000). Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol, 20(2), 429-440. doi:10.1128/mcb.20.2.429-440.2000
McLean, L. P., Smith, A., Cheung, L., Urban, J. F., Jr., Sun, R., Grinchuk, V., . . . Shea-Donohue, T. (2016). Type 3 muscarinic receptors contribute to intestinal mucosal homeostasis and clearance of Nippostrongylus brasiliensis through induction of TH2 cytokines. Am J Physiol Gastrointest Liver Physiol, 311(1), G130-141. doi:10.1152/ajpgi.00461.2014
Meier, T., & Wallace, B. G. (1998). Formation of the neuromuscular junction: molecules and mechanisms. Bioessays, 20(10), 819-829. doi:10.1002/(SICI)1521-1878(199810)20:10<819::AID-BIES7>3.0.CO;2-N
Mukund, K., Mathewson, M., Minamoto, V., Ward, S. R., Subramaniam, S., & Lieber, R. L. (2014). Systems Analysis of Transcriptional Data Provides Insights Into Muscle's Biological Response to Botulinum Toxin. Muscle Nerve. doi:10.1002/mus.24211
Mukund, K., Ward, S. R., Lieber, R. L., & Subramaniam, S. (2018). Co-Expression Network Approach to Studying the Effects of Botulinum Neurotoxin-A. IEEE/ACM Trans Comput Biol Bioinform, 15(6), 2009-2016. doi:10.1109/tcbb.2017.2763949
Narumiya, S. (1996). The small GTPase Rho: cellular functions and signal transduction. J Biochem, 120(2), 215-228. doi:10.1093/oxfordjournals.jbchem.a021401
Nigam, P. K., & Nigam, A. (2010). Botulinum toxin. Indian journal of dermatology, 55(1), 8-14. doi:10.4103/0019-5154.60343
Oh, S. H., Lee, Y., Seo, Y. J., Lee, J. H., Yang, J. D., Chung, H. Y., & Cho, B. C. (2012). The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg, 38(10), 1689-1694. doi:10.1111/j.1524-4725.2012.02504.x
Olsen, D. R., Peltonen, J., Jaakkola, S., Chu, M. L., & Uitto, J. (1989). Collagen gene expression by cultured human skin fibroblasts. Abundant steady-state levels of type VI procollagen messenger RNAs. J Clin Invest, 83(3), 791-795. doi:10.1172/JCI113959
Park, C. Y., Zhuang, W., Lekhanont, K., Zhang, C., Cano, M., Lee, W. S., . . . Chuck, R. S. (2007). Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model. Mol Vis, 13, 2222-2232.
Park, T. H., Park, J. H., Chang, C. H., & Rah, D. K. (2016). Botulinum Toxin A Upregulates Rac1, Cdc42, and RhoA Gene Expression in a Dose-Dependent Manner: In Vivo and in Vitro Study. J Craniofac Surg, 27(2), 516-520. doi:10.1097/scs.0000000000002272
Pedersen, J. E., Bergqvist, C. A., & Larhammar, D. (2018). Evolution of the Muscarinic Acetylcholine Receptors in Vertebrates. eNeuro, 5(5). doi:10.1523/ENEURO.0340-18.2018
Ross, R. A., Spengler, B. A., & Biedler, J. L. (1983). Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst, 71(4), 741-747.
Ruscheweyh, R., Forderreuther, S., Gaul, C., Gendolla, A., Holle-Lee, D., Jurgens, T., . . . Straube, A. (2018). [Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society]. Nervenarzt, 89(12), 1355-1364. doi:10.1007/s00115-018-0534-0
Sandrini, G., De Icco, R., Tassorelli, C., Smania, N., & Tamburin, S. (2017). Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain, 18(1), 38. doi:10.1186/s10194-017-0744-z
Scherf, J. M., Hu, X. S., Tepp, W. H., Ichtchenko, K., Johnson, E. A., & Pellett, S. (2014). Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative. PLoS One, 9(10), e111238. doi:10.1371/journal.pone.0111238
Schiavo, G., Matteoli, M., & Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. Physiol Rev, 80(2), 717-766. doi:10.1152/physrev.2000.80.2.717
Shen, J., Ma, J., Lee, C., Smith, B. P., Smith, T. L., Tan, K. H., & Koman, L. A. (2006). How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats. J Orthop Res, 24(5), 1128-1135. doi:10.1002/jor.20131
Thirunavukkarasusx, N., Ghosal, K. J., Kukreja, R., Zhou, Y., Dombkowski, A., Cai, S., & Singh, B. R. (2011). Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin. Biochem Biophys Res Commun, 405(4), 684-690. doi:10.1016/j.bbrc.2011.01.102
Wang, L., Sun, Y., Yang, W., Lindo, P., & Singh, B. R. (2014). Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. doi:10.1016/j.toxicon.2014.02.004
Wheeler, A., & Smith, H. S. (2013). Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology, 306, 124-146. doi:10.1016/j.tox.2013.02.006
Wissel, J. (2018). Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies. Toxicon, 147, 100-106. doi:10.1016/j.toxicon.2018.01.018
Xiao, Z., & Qu, G. (2012). Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules, 17(2), 2169-2177. doi:10.3390/molecules17022169
Xiaoxue, W., Xi, C., & Zhibo, X. (2014). Effects of botulinum toxin type A on expression of genes in keloid fibroblasts. Aesthet Surg J, 34(1), 154-159. doi:10.1177/1090820X13482938
Table 1. Top five groups among the 122 identified DAVID functional groups
|
Gene Function Group |
# of Genes count |
% of Genes |
p-Value |
Probe # with > 2 fold change |
Fold change range |
|
Alternative splicing |
660 |
60.44 |
2.74E-21 |
79↑ 64↓ |
19.41~2.03 26.63~2.02 |
|
protein binding |
566 |
51.83 |
5.45E-12 |
47↑ 66↓ |
32.28~2.03 31.23~2.01 |
|
Phosphoprotein |
560 |
51.28 |
3.77E-25 |
54↑ 64↓ |
32.28~2.03 31.23~2.01 |
|
splice variant |
517 |
47.34 |
1.27E-18 |
66↑ 52↓ |
11.66~2.03 26.63~2.01 |
|
Nucleus |
363 |
33.24 |
1.51E-14 |
29↑ 34↓ |
16.95~2.03 31.23~2.01 |
Table 2. BoNT/A effects with gene list and fold changes from the DAVID Analysis
|
DAVID Analysis: Functional Annotation Groups |
Gene Title (Gene Symbol) |
Fold change 48 hr vs. 4 hr |
|
Nervous system development |
cholinergic receptor, muscarinic 3 (CHRM3) sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1) neural epidermal growth factor-like EGFL like 1 (NELL1) |
32.28 ↑ 17.07 ↑ 16.95↑ |
|
Proteinaceous extracellular matrix |
collagen, type I, alpha 2 (COL1A2) |
11.99 ↓ |
|
Signaling pathways regulating pluripotency of stem cells |
inhibitor of DNA binding 3, dominant negative helix-loop-helix protein (ID3) inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2) |
8.13 ↓ 31.23 ↓ |
|
Cellular function and signal transduction |
Rho GTPase activating protein 36 (ARHGAP36) |
11.66↑ |
|
Apoptosis |
insulin like growth factor binding protein 3 (IGFBP3) serum/glucocorticoid regulated kinase 1 (SGK1) |
13.26 ↓ 26.63 ↓ |
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 18 Jun, 2020
No community comments so far
Reviewer #2 agreed
On 19 Jun, 2020
Reviewers invited
Invitations sent on 16 Jun, 2020
Reviewer #1 agreed
On 16 Jun, 2020
Review #1 received
Received 16 Jun, 2020
Editor assigned
On 15 Jun, 2020
Submission checks complete
On 15 Jun, 2020
Editor invited
On 15 Jun, 2020
No comments provided
Editorial decision: Major revision
On 14 May, 2020
Review #2 received
Received 24 Feb, 2020
Review #1 received
Received 24 Feb, 2020
Reviewer #2 agreed
On 10 Feb, 2020
Reviewer #1 agreed
On 04 Feb, 2020
Reviewers invited
Invitations sent on 02 Feb, 2020
Editor assigned
On 28 Jan, 2020
Submission checks complete
On 28 Jan, 2020
Editor invited
On 28 Jan, 2020
First submitted
On 27 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Toxicology
Learn more about our company.
This preprint is under consideration at BMC Pharmacology and Toxicology. Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.
Learn more about In Review
Research article
Dramatic neurological and biological effects by Botulinum Neurotoxin Type A on SH-SY5Y neuroblastoma cells, beyond the blockade of neurotransmitter release
Bal R. Singh
Corresponding Author
ORCiD: https://orcid.org/0000-0002-9069-1487
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 18 Jun, 2020
No community comments so far
Reviewer #2 agreed
On 19 Jun, 2020
Reviewers invited
Invitations sent on 16 Jun, 2020
Reviewer #1 agreed
On 16 Jun, 2020
Review #1 received
Received 16 Jun, 2020
Editor assigned
On 15 Jun, 2020
Submission checks complete
On 15 Jun, 2020
Editor invited
On 15 Jun, 2020
No comments provided
Editorial decision: Major revision
On 14 May, 2020
Review #2 received
Received 24 Feb, 2020
Review #1 received
Received 24 Feb, 2020
Reviewer #2 agreed
On 10 Feb, 2020
Reviewer #1 agreed
On 04 Feb, 2020
Reviewers invited
Invitations sent on 02 Feb, 2020
Editor assigned
On 28 Jan, 2020
Submission checks complete
On 28 Jan, 2020
Editor invited
On 28 Jan, 2020
First submitted
On 27 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Toxicology
License:
This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Background Gene expression profile analysis on mammalian cell lines and animal models after exposure to botulinum neurotoxin (BoNT) have been investigated in several studies in recent years. This provides a powerful tool to identify critical signaling pathways involved in the biological and inflammatory responses to BoNT and helps to determine the mechanism of the function of botulinum toxins.
One of the key clinical characteristics of BoNT is its prolonged on-site effects. The role of BoNT on the blockage of neurotransmitter acetylcholine release in the neuromuscular junction has been well established. However, the effects of the treatment time of BoNT on the human cellular model and its potential mechanism remain to be defined. This study is aimed to use the gene microarray technology to compare the two physiological critical time points of BoNT type A (BoNT/A) treatment of human neuroblastoma cells and to advance our understanding of the profound biological influences that toxin molecules play in the neuronal cellular system.
Results SH-SY5Y cells were treated with BoNT/A for 4 and 48 hours which represent the time needed for the entrance of toxin into the cells and the time necessary for the initial appearance of the on-site effects after BoNT application. A comparison of the two time points identified 122 functional groups that are significantly changed. The top five groups are the alternative splicing, phosphoprotein, nucleus, cytoplasm, and acetylation. Furthermore, after 48 hours there were 744 genes significantly up-regulated and 624 genes significantly down-regulated (p‹ 0.01). These genes fell into the following neurological and biological annotation groups: Nervous system development, proteinaceous extracellular matrix, signaling pathways regulating pluripotency of stem cells, cellular function and signal transduction, and apoptosis.
We have also noticed that the up-regulated groups contained neuronal cell development, nervous system development, and metabolic processes while the down-regulated groups contained many chromosomes and cell cycle categories.
Conclusions The effects of BoNT/A on neuronal cells extend beyond blocking the neurotransmitter release, and that BoNT/A is a multifunctional molecule that can evoke profound cellular responses which warrant a more in-depth understanding of the mechanism of the toxin’s effects after administration.
Figure 1
Figure 2
Figure 3
Besides being known as the most potent poison known to humankind which causes botulism, Botulinum neurotoxin (BoNT) is also a multifunctional molecule which can be used to treat medical conditions such as muscle hyperactivity (Brisinda, Civello, Albanese, & Maria, 2003), neuromuscular disorders (Coffield, 2003), various types of pain (Ruscheweyh et al., 2018), and treatment of wrinkles(Jacob, 2003). New applications of BoNT have been continuously discovered in the past decade (Ghanem, Raheem, AbdelRahman, Johnson, & Abdel-Raheem, 2018; Sandrini, De Icco, Tassorelli, Smania, & Tamburin, 2017; Wissel, 2018). The mechanisms for BoNT to cause botulism have been well established. BoNT acts preferentially on peripheral cholinergic nerve terminals to inhibit acetylcholine release resulting in flaccid muscle paralysis (Schiavo, Matteoli, & Montecucco, 2000). However, the mechanisms of BoNT as an effective treatment for multiple medical conditions are currently unclear.
Among all the seven toxin serotypes produced by C. botulinum, both BoNT type A (BoNT/A) and type B (BoNT/B) are used in treating medical conditions, and the duration of BoNT/A has the most sustained action in both laboratory animals and human beings. In an effort to investigate the mechanisms of BoNT as an effective neuromedicine, more and more studies indicate that BoNT is not only a toxin but also a multifunctional molecule that participates in the regulation of gene expressions and metabolic pathways (Y. J. Kim et al., 2015; Mukund, Ward, Lieber, & Subramaniam, 2018; T. H. Park, Park, Chang, & Rah, 2016). BoNT/A has been shown to influence cellular dynamics via the modification of cellular apoptosis and cellular proliferation, which can play a role in the expression of genes relevant to abnormal fibroblast proliferation (Xiaoxue, Xi, & Zhibo, 2014). In the murine alveolar macrophage RAW264.7 cell line, microarray analysis reveals that BoNT/A induces host immune cell response through a TLR2-dependent manner (Y. J. Kim et al., 2015), and in another study, BoNT/B has been shown to induce the expression of multiple proinflammatory cytokine genes in a murine dry eye model (C. Y. Park et al., 2007). A previous microarray study in SH-SY5Y cells from our group has found that there were significant changes of genes that involved in neuroinflammatory, ubiquitin-proteasome degradation, and calcium signaling after BoNT/A treatment compared to the untreated control culture (Thirunavukkarasusx et al., 2011). However, most of the current cellular gene expression studies were conducted at one fixed time point; the genomic responses to BoNTs across different time periods have not been fully clarified.
A transcriptomic profiling study that examined the effects of BoNT/A on rat tibialis anterior muscles over one year identified dramatic transcriptional adaptation effects to BoNT/A (Mukund et al., 2014). Another microarray analysis study has investigated the muscle recovery from paresis and atrophy after intramuscular injection of BoNT/A in Juvenile rats. The microarray transcriptional profiling and real-time-PCR analysis identified a sequence of cellular events that leads to the neuromuscular junction regeneration and skeletal muscle functional recovery, and the insulin-like growth factor-1 (IGF-1) signaling pathway is proven to play a central role in the process (Shen et al., 2006). None of the studies, however, have examined the progression of the BoNT effect on gene expression with time. Microarray analysis that focuses on the cellular response over a period of time will provide new insight into the critical signaling pathways involved in the biological and inflammatory responses to BoNT.
In vitro models for the entry of BoNT into neurons have shown that at least 4-hours is needed for BoNT to enter the neuron cells (Dong et al., 2008). Our group has also observed the binding and co-localization of BoNT/A with intracellular structures in SH-SY5Y cells after 4-hours of treatment (Wang, Sun, Yang, Lindo, & Singh, 2014). In both the clinical administrations of BoNT and the in vivo or in vitro BoNT treatment systems, the on-site effect usually takes about 24 to 72 hours (Nigam & Nigam, 2010). In addition, a previous study from our group has observed a significant increase of proinflammatory cytokines release from the SH-SY5Y cells after 48-hours of BoNT/A treatment (Wang et al., 2014) indicating the effectiveness of the duration on evoking the cellular response.
Our current study aims to explore the differences of gene expression profiles in human neuroblastoma SH-SY5Y cells after exposure to BoNT/A at two physiological critical time points: at 4-hours when BoNT/A has made its entry into the cells and at the time of the observation of evoked host responses by BoNT/A which is usually 48-hours. Comparative analysis of gene expression at the two time points identified 122 functional groups that are significantly changed in the neuronal cells. The top five groups are alternative splicing, phosphoprotein, nucleus, cytoplasm, and acetylation. Furthermore, 744 genes were significantly up-regulated after 48 hours, and 624 genes were significantly down-regulated (p‹ 0.01). These genes generally belonged to nervous system development, proteinaceous extracellular matrix, signaling pathways regulating pluripotency of stem cells, cellular function and signal transduction, and apoptosis, suggesting a substantial biological and neurological impact of BoNT treatment.
2.1 Materials
The 150 kDa BoNT/A holotoxin was purchased from Metabiologics Inc. (Madison, WI). The toxin was produced by a Hall A strain of Clostridium botulinum. Toxin activity for the holotoxin was 2.1x107 MLD50/mg according to the manufacturer. The human neuroblastoma cell line SH-SY5Y was obtained from the American Type Culture Collection (ATCC, Manassas, VA). Tissue culture media were ATCC-formulated Eagle’s Minimum Essential Medium (ATCC) with 10% fetal bovine serum (ATCC). Other materials and reagents include Ethanol (70% and 96-100%), Sterile, RNase-free pipet tips, 1.5 ml or 2 ml microcentrifuge tubes, Microcentrifuge for centrifugation at 4 ⁰C and at room temperature. 60 mm treated petri dishes (Lab-Tek II, Nalge Nunc International, Naperville, IL). 4% Paraformaldehyde (Sigma-Aldrich, St. Louis, MO). miRNeasy Mini Kit (Qiagen).
2.2 Cell culture and treatments
The SH-SY5Y cell line, derived from human brain neuroblastoma (Ross, Spengler, & Biedler, 1983), grown and maintained as recommended by ATCC, was maintained with 10% FBS in 5% CO2/humidified air at 37⁰C. SH-SY5Y cells grew as a mixture of floating and adherent cells. The base growth medium was 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium and F12 Medium. To complete the growth medium, fetal bovine serum was added to a final concentration of 10%. The SH-SY5Y cells were seeded at a density of 2×105 cells/well in 60 mm treated petri dishes and grew for 2 days when reaching the 80% confluence before treatment with serum-free media containing 5 nM of BoNT/A for 4 and 48-hours in duplicates.
2.3 RNA extraction
The following protocol was developed from manufacturer Qiagen’s manuals with modifications. At the end of treatment, QIAzol Lysis Reagent was used to added to disrupt and homogenize the SH-SY5Y cells. The upper aqueous phase was collected and treated with 100% ethanol and transferred into the RNeasy Mini column in 2 ml collection tube. After centrifugations, discarded the flow-through. RNeasy Mini columns were transferred to a new 1.5 ml collection tube. Pipetted 30 ml RNase-free water directly onto the RNeasy Mini column membrane. Closed lid, centrifuged for 1 min at 8000 Xg to elute. The concentration of RNA was determined by measuring the absorbance at 260 nm in a spectrophotometer.
2.4 Microarray analysis
Genome analysis was carried out using Affymetrix U133 Plus 2 arrays. After preprocessing and normalization of the data, differentially expressed genes were identified by performing an analysis of variance using Partek Genomics Suite software (Partek Inc., St. Louis, MO). A gene list was created by filtering for p-value <0.01. This subset of 1368 genes was further analyzed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 to identify biologically enriched groups (Huang da, Sherman, & Lempicki, 2009a, 2009b).
The current study identified 1,368 differentially expressed genes between the two time points. As presented in the heat map in Figure 1, 744 genes were up-regulated, and 624 genes were down-regulated, indicating that there are significant differences between the gene expression profile for 48 and 4-hour treatment of the SH-SY5Y cells.
Among the 1,368 differentially expressed genes of the 48-hour to 4-hour treatment, we conducted DAVID analysis and identified 122 functional groups that have been significantly changed in the SH-SY5Y cells. Figure 2 shows the functional annotation chart of the top 20 functional groups according to the number of genes involved.
We took a closer look into the five groups which have involved the most numbers of genes out of the 20 top functional groups and included the results in Table 1. The results table include the numbers of involved genes, p-value, the numbers of up- or down-regulated genes (probe), and the fold change range for up- and down-regulation. These five groups are alternative splicing, phosphoprotein, nucleus, cytoplasm, and acetylation. These results indicate that following the entrance of BoNT/A into the SH-SY5Y cells after 4-hour treatment, when the BoNT/A incubation reaches the 48-hours, different cellular transcription, modification, and signaling transduction pathways ensue with profound cellular responses resulting from dramatic gene fold changes.
We have further investigated the major annotation groups that are involved in neuronal and biological functions. The complete gene list with more than 2-fold change are shown in the following supplement tables: neurological function (Supplement Table 1), neurological cellular response (Supplement Table 2), cell structure related function (Supplement Table 3), and the cell fate determination (Supplement Table 4). In each of these groups, genes were listed according to their DAVID annotation group with the fold change of up- or down-regulation.
Based on the results in Supplement Table 1 through 4, we generated Table 2 below that provides a highlight of the genes with more than 8-fold change after 48-hour treatment. The genes are listed according to their annotation groups.
Dramatic up-regulation of genes involved in acetylcholine receptor and other extracellular components
In the nervous system development annotation group, compared to the 4-hour treatment, three genes have been significantly up-regulated after 48-hour treatment: CHRM3, SPOCK1, and NELL1.
The cholinergic receptor muscarinic 3 (CHRM3) that encodes the CHRM3 receptor has a 32.28-fold increase (p<0.002). The muscarinic receptors (MRs) are G protein-coupled receptors that mediate cholinergic neurotransmission (Eglen, 2006; Pedersen, Bergqvist, & Larhammar, 2018). The CHRM3 receptor responds to the transmitter acetylcholine (Pedersen et al., 2018). The role of muscarinic receptors in the contraction of smooth muscle, particularly of airway, ileum, iris, and bladder, is considered a classical muscarinic response mediated primarily by M3-muscarinic receptors expressed on the smooth muscle cells (Caulfield, 1993). Five MR are identified (designated M1R–M5R, encoded by CHRM1-5). Post-MR signaling involves activation of phospholipase C with subsequent changes in cellular levels of inositol phosphate, cAMP, and calcium (McLean et al., 2016).
The sparc/osteonectin cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1) gene that encodes the protein Testican has a 17.07-fold increase (p<0.002). Testican is a human testicular proteoglycan which contains the extracellular calcium-binding module (Alliel, Perin, Jolles, & Bonnet, 1993). Immunostaining in the adult normal mouse muscle has shown the co-localization of SPOCK and acetylcholine receptor (AChR) clusters (Cifuentes-Diaz et al., 2000).
The NELL1 gene, which is a secretory osteogenic protein and functions as an extracellular matrix component (Li et al., 2018) has a 16.95 fold increase (p<0.002). The dramatic expression increase of this group of genes after 48-hour treatment indicates that after the acetylcholine release being blocked by BoNT/A, the genes involved in the expression of the acetylcholine responsive receptor, the extracellular components in the SH-SY5Y cells are dramatically up-regulated, highly possible to compensate the transmitter loss.
Another significantly up-regulated gene is Rho GTPase activating protein 36 (ARHGAP36) whose expression increased 11.66-fold (p<0.003). Rho, a Ras homologue of small GTPase, is present from yeast to mammals. It shuttles between the active GTP-bound form and the inactive GDP-bound form and works as a switch in stimulus-evoked cell adhesion and motility, enhancement of contractile responses, and cytokinesis (Narumiya, 1996). In these actions, Rho directs the reorganization of the actin cytoskeleton at a specific time and a particular site in the cell (Hall, 1992). ARHGAP36 is expressed in neuroblastoma cells and promotes aberrant activation of the Hedgehog pathway and inhibits Protein kinase A (PKA) signaling (Eccles et al., 2016). PKA is a key mediator of cAMP signaling downstream of G-protein-coupled receptors, a signaling pathway conserved in all eukaryotes. The up-regulation of ARHGAP36, in turn, dampens the sensitivity of cells to cAMP (Eccles et al., 2016).
Significant downregulation of genes for collagen deposition and cellular differentiation and apoptotic factors
Collagen type I makes up 90% of the collagen in the human body, and its function is to give the tissue resistance to force. Collagen type I is also one of the main components of the human skin dermis. The gene COL1A1 and COL1A2 encode the pro-alpha 1 and pro-alpha 2 chains of type I collagen, respectively (Olsen, Peltonen, Jaakkola, Chu, & Uitto, 1989). Compared to 4-hour treatment, we observed an 11.99-fold decrease (p<0.009) of COL1A2 gene expression after 48 hours. However, the Collagen-degrading matrix metalloproteinases (MMPs) gene expression did not show a significant difference between our 48 and 4-hour treatment. This finding indicates that although BoNT/A has down-regulation effects on the collagen extracellular matrix formation genes, the collagen degradation genes are not influenced by the 48 vs. 4-hour treatment.
We have also identified the downregulation of several genes that are involved in cell differentiation and survival. There are four known inhibitors of DNA binding (ID) proteins (ID1, ID2, ID3, andID4) which share a homologous HLH domain, but lack the basic DNA binding region. The basic helix-loop-helix (bHLH) family of transcription factors are critical cell type determinants that play essential roles in cellular differentiation (Massari & Murre, 2000). We observed an 8.13 (p<0.006) and 31.23 (p<0.001)-fold down-regulation of ID3 and ID2, respectively. ID3 also regulates cytokines, including chemokine (C–X–C motif) ligand 1 previously known as GRO1, interleukin-6 (IL-6) and IL-8 (Jin et al., 2011). We have observed a 13.26 fold decrease (p<0.005) in the insulin-like growth factor binding protein 3 (IGFBP3). IGFBP regulates the bioavailability and bioactivity of insulin-like growth factor (IGF). The major IGFBP in serum is IGFBP-3. IGFBP-3 regulates IGF bioactivity and also independently modulates cell growth and survival (Dake, Boes, Bach, & Bar, 2004). There is also a 26.63-fold decrease (p<0.007) of serum- and glucocorticoid-inducible kinase 1 (SGK1) genes that belong to the AGC family of kinases and have been shown to have various cellular functions, including the promotion of cell survival.
BoNT/A evokes profound up and down-regulation of genes to impact physiological processes in SH-SY5Y cells
Besides looking into individual genes, to generate a thorough understanding of the effects of BoNT/A on the neurological and biological annotation groups, we ran a further analysis of the genes and determined whether the 48-hour treatment evokes the up- or down-regulation of different annotation groupsas shown in Figure 3. Interestingly, there were no overlaps in the functional groups between the two up- and down-regulation group sets.We have also noticed that the up-regulated groups contained neuronal cell development, nervous system development, and metabolic processes; the down-regulated groups contained many chromosomes and cell cycle categories. These data indicate that BoNT/A treatment has profound effects on the neuronal and non-neuronal functions of SH-SY5Y cells. Moreover, the up and down-regulation of genes is coordinated to impact physiological processes.
Nerve terminal intoxication and the medical application of BoNT/A are fully reversible and are not reported to lead to any neurodegeneration. After the synaptic blockade of cholinergic nerve terminals, new synapses are formed by the neuron (sprouting) to replace its original ones (de Paiva, Meunier, Molgo, Aoki, & Dolly, 1999). In the cellular model of cerebellar granule cells, BoNT/A did not trigger neurite degeneration or apoptosis up to 72-hour treatment (Berliocchi et al., 2005). In this study, we have demonstrated that BoNT/A significantly modified genes involved in the annotation group of nervous system development and the proteinaceous extracellular matrix. The three genes CHRM3, SPOCK1, and NELL1 have been increased 32.28, 17.07, and 16.95 fold, respectively (Table 2). A study in the human induced pluripotent stem cell (hiPSC)-derived neurons also found that BoNT/A induced the upregulation of CHRM3 by 9 fold compared to the non-treated control which promotes the neurite outgrowth (Huh et al., 2009; Scherf et al., 2014). The SPOCK1 gene encoded the protein testican whose functions are to regulate cell shape and gene expression, cell adhesion processes, and neurogenesis (Lane & Sage, 1994). This protein has also been shown to contribute to neuron-neuron synapse development and is involved in neuron-muscle synapse development (Kohfeldt, Maurer, Vannahme, & Timpl, 1997; Meier & Wallace, 1998). In a mature mouse model, the co-localization of SPOCK protein and acetylcholine receptor (AChR) clusters has been observed (Cifuentes-Diaz et al., 2000). But botulinum toxins have been shown to induce a remodeling of AChR clusters (Koltgen, Ceballos-Baumann, & Franke, 1994), and AChR clusters devoid of SPOCK were observed after BoNT/A injection in an extensor digitorum longus muscle model (Cifuentes-Diaz et al., 2000). In our study, this effect may also interact with the up-regulation of CHRM3, which activates the phospholipase C and, in turn, modifies the cellular level of cAMP. The evoking of a series of signal transduction effort in the cell after BoNT/A 48-hour treatment demonstrates that the modification of cellular function and signal transduction are part of the on-site effects of BoNT/A. These data indicate that although we observed the significant up-regulation of CHRM3 and SPOCK1 genes which may, in turn, promote the increase of the expression of the receptors in the cells, this doesn’t gurantee the rise in the co-localization of the clusters of the related receptors. This finding calls attention to the further investigation of these receptors and their downstream signaling after BoNT/A treatment.
In addition to the genetic mechanism involved in the intoxication recovery, we have also identified the effects of BoNT/A in other biological functions as a neuromedicine. BoNT has been shown to inhibit hypertrophic scar formation (Xiao & Qu, 2012) and modulate the release of various neurotransmitters, such as glutamate and substance P, which will help reduce scar hypertrophy (Al-Qattan, Al-Shanawani, & Alshomer, 2013). We have identified the expression of different genes involved in collagen deposition in hypertrophic scars, and neurotransmitters that are involved in scar formation (Table 2 and Supplement Table 2). We observe an 11.99 fold decrease of the COL1A2 gene expression after 48-hour treatment compared to 4-hour. The gene COL1A1 and COL1A2 encode the pro-alpha 1 and pro-alpha 2 chains of type I collagen, respectively. Collagen type I makes up 90% of the collagen in the human body, and its function is to give the tissue resistance to force. Collagen type I is also one of the main components of the human skin dermis (Olsen et al., 1989). In our study, the Collagen-degrading matrix metalloproteinases (MMPs) gene expression did not show a significant difference between our 48 and 4-hour treatment groups. BoNT/A has been shown to block the syntheses of collagen types 1 and 3 in human fibroblasts upon the stimulation with TGF (S. Kim et al., 2016). In another study on the human dermal fibroblasts, type III collagen mRNA expression has been significantly decreased when BoNT/A was administrated on KFs regardless of the presence or absence of TGF-ß (Oh et al., 2012).
It has been reported that BoNT/A inhibits the release of various neurotransmitters (e.g., glutamate and substance P), which inhibits the release of inflammatory mediators such as bradykinin, prostaglandins, and serotonin.6 (Al-Qattan et al., 2013). A previous microarray study in SH-SY5Y cells from our group has found that there were significant changes of genes that involved in neuroinflammatory, ubiquitin-proteasome degradation, and calcium signaling after BoNT/A treatment compared to the untreated control culture (Thirunavukkarasusx et al., 2011). Our data (Supplement Table 3) shows the profound effects of BoNT/A in the cytoskeleton involved genes after 48-hour treatment. In addition, as shown in Table 2, the signaling pathways regulating the pluripotency of stem cells, cell division, and apoptosis functions have also been significantly modified by the 48-hour treatment. These included key regulators that signal cytoskeletal remodeling steps in pathways related to vesicle trafficking, axonal growth, and cell migration. These proteins included the Rho GTPase, Ras-GAP SH3 binding protein, Rho GTPase activating protein, actin-related protein, and actin, which affect the phosphorylation of proteins involved in cytoskeletal remodeling pathways (Lee, Ahn, Park, & Park, 2016). We have also observed a 26.6-fold decrease of SGK1 genes. Several observations point to a physiological role of SGK1 in cell cycle progression (Buse et al., 1999) and cell survival pathways. The upregulation of SGK1 strongly correlates with the occurrence of cell death (Schoenebeck et al., 2005). Our data indicate that BoNT/A has a strong inhibition effect on SGK1 expression, which may prevent the apoptosis of the SH-SY5Y cells.
No currently available publication has explored the effects of BoNT/A on the inhibition of DNA binding 2 or 3 (ID2 or ID3) expression. We have observed an 8.13 and 31.23 fold down-regulation of ID3 and ID2. In a study using human glioma cell line Hs683, candoxin which is a three-finger neurotoxin purified from the venom of the Malayan krait (Bungarus candidus) snake has been shown to downregulate ID3 which inhibits glioma cell proliferation (Jiang, Ma, & Cheng, 2012). The cytokines that regulated by ID3 genes, including chemokine (C–X–C motif) ligand one previously known as GRO1, interleukin-6 (IL-6), and IL-8 (Jin et al., 2011). Our data indicate that BoNT/A has the capability of modifying DNA binding factors, which may link to the longevity of BoNT/A treatment since the BoNT/A effect is extended into the transcriptional regulation and is not solely determined by the toxin protein half-life in the application sites. This observation sheds light on another mechanism to explain why the on-site effects of the BoNT/A treatment can last up to 16 weeks.
One of the advantages of BoNT/A medicinal application is the local effect at the neuromuscular junction (NMJ), resulting in flaccid paralysis. It has been believed that BoNT inhibits synaptic transmission only near the site of injection (Wheeler & Smith, 2013). However, there has been evidence questioning this idea after physicians utilized this agent in human patients. For example, after peripheral injection of BoNT/A, reciprocal inhibition between agonist and antagonist muscles has been reported, raising the possibility that BoNT/A moves within networks of neurons to affect circuit function (Aymard, Giboin, Lackmy-Vallee, & Marchand-Pauvert, 2013; Marchand-Pauvert et al., 2013). Alternatively, the observed effects might be due to the compensatory reorganization and remodeling of neuronal networks upstream of the injection site, as a result of purely local effects on the initial uptake neurons (Abbruzzese & Berardelli, 2006; Boroojerdi, Cohen, & Hallett, 2003; Curra, Trompetto, Abbruzzese, & Berardelli, 2004). In a study conducted in the compartmentalized microfluidic devices, BoNT/A and D have undergone interneuronal transfer to affect networks of neurons (Bomba-Warczak et al., 2016). These findings suggest a possible mechanism for the potential side effects after the BoNT application.
The primary conclusion of the current study is that botulinum neurotoxin type A can cause dramatic neurological and biological effects on SH-SY5Y neuroblastoma cells. From the time BoNT/A enters the SH-SY5Y cells at 4-hours to the evoking of on-site effects of BoNT/A after 48-hours, the toxin has profound influences on gene expression profiles of SH-SY5Y cells. We identified significant expression changes of genes in the functional groups of nervous system development, proteinaceous extracellular matrix, signaling pathways regulating pluripotency of stem cells, cellular function and signal transduction, and apoptosis. Up-regulated groups contained neuronal cell development, nervous system development, and metabolic processes; while the down-regulated groups contained many chromosomes and cell cycle categories. Collectively, this experimental evidence strongly supports the overall conclusion that BoNT/A has profound neurological and biological effects on human neuroblastoma SH-SY5Y cells, which extend beyond the neurotransmitter release blockage. Our research warrants a more in-depth understanding of the mechanism of the toxin’s effects after the administration, which will help to understand the development of botulism disease and its longevity and explain the effectiveness of BoNT-related biomedicineIn future studies we plan to include treatment times longer than 48 hours which will provide more comprehensive data for the understanding of the mechanism of the toxin’s effects after administration. Our data and the clinical evidence demonstrate that BoNT interacts with host systems in a more sophisticated manner than was initially envisioned, prompting the need for further investigations of the neurons and non-neuronal biology after the BoNT application.
BoNT, botulinum neurotoxin; BoNT/A, botulinum neurotoxin type A; HC, heavy chain; LC, light chain; IGF-1, insulin-like growth factor-1; IL-6, interleukin-6
Ethics approval and consent to participate
Not applicable
Consent to publish
Not applicable
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.
Competing interests
The authors declare that they have no competing interests
Funding
This work was supported by Merz Pharmaceuticals, Frankfurt, Germany, and Maryada Foundation.
Authors' Contributions
LW, data curation, investigation, writing – original draft preparation
CSR, formal analysis, writing – review, and editing
BRS: supervision, writing- review, and editing, corresponding author.
All authors read and approved the final manuscript
Acknowledgments
Data analysis for this project was carried out at Dartmouth Medical School in the Genomics Shared Resource with the assistance from Dr. Fred Kolling IV.
Abbruzzese, G., & Berardelli, A. (2006). Neurophysiological effects of botulinum toxin type A. Neurotox Res, 9(2-3), 109-114.
Al-Qattan, M. M., Al-Shanawani, B. N., & Alshomer, F. (2013). Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. Ann Saudi Med, 33(5), 482-488. doi:10.5144/0256-4947.2013.482
Alliel, P. M., Perin, J. P., Jolles, P., & Bonnet, F. J. (1993). Testican, a multidomain testicular proteoglycan resembling modulators of cell social behaviour. Eur J Biochem, 214(1), 347-350.
Aymard, C., Giboin, L. S., Lackmy-Vallee, A., & Marchand-Pauvert, V. (2013). Spinal plasticity in stroke patients after botulinum neurotoxin A injection in ankle plantar flexors. Physiol Rep, 1(6), e00173. doi:10.1002/phy2.173
Berliocchi, L., Fava, E., Leist, M., Horvat, V., Dinsdale, D., Read, D., & Nicotera, P. (2005). Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis. J Cell Biol, 168(4), 607-618. doi:10.1083/jcb.200406126
Bomba-Warczak, E., Vevea, J. D., Brittain, J. M., Figueroa-Bernier, A., Tepp, W. H., Johnson, E. A., . . . Chapman, E. R. (2016). Interneuronal Transfer and Distal Action of Tetanus Toxin and Botulinum Neurotoxins A and D in Central Neurons. Cell reports, 16(7), 1974-1987. doi:10.1016/j.celrep.2016.06.104
Boroojerdi, B., Cohen, L. G., & Hallett, M. (2003). Effects of botulinum toxin on motor system excitability in patients with writer's cramp. Neurology, 61(11), 1546-1550. doi:10.1212/01.wnl.0000095965.36574.0f
Brisinda, G., Civello, I. M., Albanese, A., & Maria, G. (2003). Gastrointestinal smooth muscles and sphincters spasms: treatment with botulinum neurotoxin. Curr Med Chem, 10(7), 603-623.
Caulfield, M. P. (1993). Muscarinic receptors--characterization, coupling and function. Pharmacol Ther, 58(3), 319-379. doi:10.1016/0163-7258(93)90027-b
Cifuentes-Diaz, C., Alliel, P. M., Charbonnier, F., de la Porte, S., Molgo, J., Goudou, D., . . . Perin, J. P. (2000). Regulated expression of the proteoglycan SPOCK in the neuromuscular system. Mech Dev, 94(1-2), 277-282.
Coffield, J. A. (2003). Botulinum neurotoxin: the neuromuscular junction revisited. Crit Rev Neurobiol, 15(3-4), 175-196.
Curra, A., Trompetto, C., Abbruzzese, G., & Berardelli, A. (2004). Central effects of botulinum toxin type A: evidence and supposition. Mov Disord, 19 Suppl 8, S60-64. doi:10.1002/mds.20011
de Paiva, A., Meunier, F. A., Molgo, J., Aoki, K. R., & Dolly, J. O. (1999). Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A, 96(6), 3200-3205.
Dong, M., Liu, H., Tepp, W. H., Johnson, E. A., Janz, R., & Chapman, E. R. (2008). Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Molecular biology of the cell, 19(12), 5226-5237. doi:10.1091/mbc.E08-07-0765
Eccles, R. L., Czajkowski, M. T., Barth, C., Müller, P. M., McShane, E., Grunwald, S., . . . Rocks, O. (2016). Bimodal antagonism of PKA signalling by ARHGAP36. Nat Commun, 7, 12963. doi:10.1038/ncomms12963
Eglen, R. M. (2006). Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol, 26(3), 219-233. doi:10.1111/j.1474-8673.2006.00368.x
Ghanem, H., Raheem, A. A., AbdelRahman, I. F. S., Johnson, M., & Abdel-Raheem, T. (2018). Botulinum Neurotoxin and Its Potential Role in the Treatment of Erectile Dysfunction. Sex Med Rev, 6(1), 135-142. doi:10.1016/j.sxmr.2017.07.008
Hall, A. (1992). Ras-related GTPases and the cytoskeleton. Mol Biol Cell, 3(5), 475-479. doi:10.1091/mbc.3.5.475
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009a). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res, 37(1), 1-13. doi:10.1093/nar/gkn923
Huang da, W., Sherman, B. T., & Lempicki, R. A. (2009b). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc, 4(1), 44-57. doi:10.1038/nprot.2008.211
Huh, J. W., Kim, Y. H., Lee, S. R., Kim, H., Kim, D. S., Kim, H. S., . . . Chang, K. T. (2009). Gain of new exons and promoters by lineage-specific transposable elements-integration and conservation event on CHRM3 gene. Mol Cells, 28(2), 111-117. doi:10.1007/s10059-009-0106-z
Jacob, C. I. (2003). Botulinum neurotoxin type B--a rapid wrinkle reducer. Semin Cutan Med Surg, 22(2), 131-135. doi:10.1053/sder.2003.50009
Jiang, Y. X., Ma, Y., & Cheng, Y. (2012). Transcriptome and coexpression network analysis of the human glioma cell line Hs683 exposed to candoxin. J Int Med Res, 40(3), 887-898. doi:10.1177/147323001204000307
Jin, X., Yin, J., Kim, S. H., Sohn, Y. W., Beck, S., Lim, Y. C., . . . Kim, H. (2011). EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res, 71(22), 7125-7134. doi:10.1158/0008-5472.CAN-11-1330
Kim, S., Ahn, M., Piao, Y., Ha, Y., Choi, D. K., Yi, M. H., . . . Oh, S. H. (2016). Effect of Botulinum Toxin Type A on TGF-beta/Smad Pathway Signaling: Implications for Silicone-Induced Capsule Formation. Plast Reconstr Surg, 138(5), 821e-829e. doi:10.1097/prs.0000000000002625
Kim, Y. J., Kim, J. H., Lee, K. J., Choi, M. M., Kim, Y. H., Rhie, G. E., . . . Shin, N. R. (2015). Botulinum neurotoxin type A induces TLR2-mediated inflammatory responses in macrophages. PLoS One, 10(4), e0120840. doi:10.1371/journal.pone.0120840
Kohfeldt, E., Maurer, P., Vannahme, C., & Timpl, R. (1997). Properties of the extracellular calcium binding module of the proteoglycan testican. FEBS Lett, 414(3), 557-561.
Koltgen, D., Ceballos-Baumann, A. O., & Franke, C. (1994). Botulinum toxin converts muscle acetylcholine receptors from adult to embryonic type. Muscle Nerve, 17(7), 779-784. doi:10.1002/mus.880170713
Lane, T. F., & Sage, E. H. (1994). The biology of SPARC, a protein that modulates cell-matrix interactions. Faseb j, 8(2), 163-173.
Lee, J., Ahn, E., Park, W. K., & Park, S. (2016). Phosphoproteome Profiling of SH-SY5y Neuroblastoma Cells Treated with Anesthetics: Sevoflurane and Isoflurane Affect the Phosphorylation of Proteins Involved in Cytoskeletal Regulation. PLoS One, 11(9), e0162214. doi:10.1371/journal.pone.0162214
Li, C., Zheng, Z., Jiang, J., Jiang, W., Lee, K., Berthiaume, E. A., . . . Soo, C. (2018). Neural EGFL-Like 1 Regulates Cartilage Maturation through Runt-Related Transcription Factor 3-Mediated Indian Hedgehog Signaling. Am J Pathol, 188(2), 392-403. doi:10.1016/j.ajpath.2017.09.020
Marchand-Pauvert, V., Aymard, C., Giboin, L. S., Dominici, F., Rossi, A., & Mazzocchio, R. (2013). Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol, 591(4), 1017-1029. doi:10.1113/jphysiol.2012.239178
Massari, M. E., & Murre, C. (2000). Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol, 20(2), 429-440. doi:10.1128/mcb.20.2.429-440.2000
McLean, L. P., Smith, A., Cheung, L., Urban, J. F., Jr., Sun, R., Grinchuk, V., . . . Shea-Donohue, T. (2016). Type 3 muscarinic receptors contribute to intestinal mucosal homeostasis and clearance of Nippostrongylus brasiliensis through induction of TH2 cytokines. Am J Physiol Gastrointest Liver Physiol, 311(1), G130-141. doi:10.1152/ajpgi.00461.2014
Meier, T., & Wallace, B. G. (1998). Formation of the neuromuscular junction: molecules and mechanisms. Bioessays, 20(10), 819-829. doi:10.1002/(SICI)1521-1878(199810)20:10<819::AID-BIES7>3.0.CO;2-N
Mukund, K., Mathewson, M., Minamoto, V., Ward, S. R., Subramaniam, S., & Lieber, R. L. (2014). Systems Analysis of Transcriptional Data Provides Insights Into Muscle's Biological Response to Botulinum Toxin. Muscle Nerve. doi:10.1002/mus.24211
Mukund, K., Ward, S. R., Lieber, R. L., & Subramaniam, S. (2018). Co-Expression Network Approach to Studying the Effects of Botulinum Neurotoxin-A. IEEE/ACM Trans Comput Biol Bioinform, 15(6), 2009-2016. doi:10.1109/tcbb.2017.2763949
Narumiya, S. (1996). The small GTPase Rho: cellular functions and signal transduction. J Biochem, 120(2), 215-228. doi:10.1093/oxfordjournals.jbchem.a021401
Nigam, P. K., & Nigam, A. (2010). Botulinum toxin. Indian journal of dermatology, 55(1), 8-14. doi:10.4103/0019-5154.60343
Oh, S. H., Lee, Y., Seo, Y. J., Lee, J. H., Yang, J. D., Chung, H. Y., & Cho, B. C. (2012). The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg, 38(10), 1689-1694. doi:10.1111/j.1524-4725.2012.02504.x
Olsen, D. R., Peltonen, J., Jaakkola, S., Chu, M. L., & Uitto, J. (1989). Collagen gene expression by cultured human skin fibroblasts. Abundant steady-state levels of type VI procollagen messenger RNAs. J Clin Invest, 83(3), 791-795. doi:10.1172/JCI113959
Park, C. Y., Zhuang, W., Lekhanont, K., Zhang, C., Cano, M., Lee, W. S., . . . Chuck, R. S. (2007). Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model. Mol Vis, 13, 2222-2232.
Park, T. H., Park, J. H., Chang, C. H., & Rah, D. K. (2016). Botulinum Toxin A Upregulates Rac1, Cdc42, and RhoA Gene Expression in a Dose-Dependent Manner: In Vivo and in Vitro Study. J Craniofac Surg, 27(2), 516-520. doi:10.1097/scs.0000000000002272
Pedersen, J. E., Bergqvist, C. A., & Larhammar, D. (2018). Evolution of the Muscarinic Acetylcholine Receptors in Vertebrates. eNeuro, 5(5). doi:10.1523/ENEURO.0340-18.2018
Ross, R. A., Spengler, B. A., & Biedler, J. L. (1983). Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst, 71(4), 741-747.
Ruscheweyh, R., Forderreuther, S., Gaul, C., Gendolla, A., Holle-Lee, D., Jurgens, T., . . . Straube, A. (2018). [Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society]. Nervenarzt, 89(12), 1355-1364. doi:10.1007/s00115-018-0534-0
Sandrini, G., De Icco, R., Tassorelli, C., Smania, N., & Tamburin, S. (2017). Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia. J Headache Pain, 18(1), 38. doi:10.1186/s10194-017-0744-z
Scherf, J. M., Hu, X. S., Tepp, W. H., Ichtchenko, K., Johnson, E. A., & Pellett, S. (2014). Analysis of gene expression in induced pluripotent stem cell-derived human neurons exposed to botulinum neurotoxin A subtype 1 and a type A atoxic derivative. PLoS One, 9(10), e111238. doi:10.1371/journal.pone.0111238
Schiavo, G., Matteoli, M., & Montecucco, C. (2000). Neurotoxins affecting neuroexocytosis. Physiol Rev, 80(2), 717-766. doi:10.1152/physrev.2000.80.2.717
Shen, J., Ma, J., Lee, C., Smith, B. P., Smith, T. L., Tan, K. H., & Koman, L. A. (2006). How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A: Study in juvenile rats. J Orthop Res, 24(5), 1128-1135. doi:10.1002/jor.20131
Thirunavukkarasusx, N., Ghosal, K. J., Kukreja, R., Zhou, Y., Dombkowski, A., Cai, S., & Singh, B. R. (2011). Microarray analysis of differentially regulated genes in human neuronal and epithelial cell lines upon exposure to type A botulinum neurotoxin. Biochem Biophys Res Commun, 405(4), 684-690. doi:10.1016/j.bbrc.2011.01.102
Wang, L., Sun, Y., Yang, W., Lindo, P., & Singh, B. R. (2014). Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. doi:10.1016/j.toxicon.2014.02.004
Wheeler, A., & Smith, H. S. (2013). Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology, 306, 124-146. doi:10.1016/j.tox.2013.02.006
Wissel, J. (2018). Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies. Toxicon, 147, 100-106. doi:10.1016/j.toxicon.2018.01.018
Xiao, Z., & Qu, G. (2012). Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules, 17(2), 2169-2177. doi:10.3390/molecules17022169
Xiaoxue, W., Xi, C., & Zhibo, X. (2014). Effects of botulinum toxin type A on expression of genes in keloid fibroblasts. Aesthet Surg J, 34(1), 154-159. doi:10.1177/1090820X13482938
Table 1. Top five groups among the 122 identified DAVID functional groups
|
Gene Function Group |
# of Genes count |
% of Genes |
p-Value |
Probe # with > 2 fold change |
Fold change range |
|
Alternative splicing |
660 |
60.44 |
2.74E-21 |
79↑ 64↓ |
19.41~2.03 26.63~2.02 |
|
protein binding |
566 |
51.83 |
5.45E-12 |
47↑ 66↓ |
32.28~2.03 31.23~2.01 |
|
Phosphoprotein |
560 |
51.28 |
3.77E-25 |
54↑ 64↓ |
32.28~2.03 31.23~2.01 |
|
splice variant |
517 |
47.34 |
1.27E-18 |
66↑ 52↓ |
11.66~2.03 26.63~2.01 |
|
Nucleus |
363 |
33.24 |
1.51E-14 |
29↑ 34↓ |
16.95~2.03 31.23~2.01 |
Table 2. BoNT/A effects with gene list and fold changes from the DAVID Analysis
|
DAVID Analysis: Functional Annotation Groups |
Gene Title (Gene Symbol) |
Fold change 48 hr vs. 4 hr |
|
Nervous system development |
cholinergic receptor, muscarinic 3 (CHRM3) sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 (SPOCK1) neural epidermal growth factor-like EGFL like 1 (NELL1) |
32.28 ↑ 17.07 ↑ 16.95↑ |
|
Proteinaceous extracellular matrix |
collagen, type I, alpha 2 (COL1A2) |
11.99 ↓ |
|
Signaling pathways regulating pluripotency of stem cells |
inhibitor of DNA binding 3, dominant negative helix-loop-helix protein (ID3) inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2) |
8.13 ↓ 31.23 ↓ |
|
Cellular function and signal transduction |
Rho GTPase activating protein 36 (ARHGAP36) |
11.66↑ |
|
Apoptosis |
insulin like growth factor binding protein 3 (IGFBP3) serum/glucocorticoid regulated kinase 1 (SGK1) |
13.26 ↓ 26.63 ↓ |